Business News • MarketWire • Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms |
Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms |
|
|
Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms
JERUSALEM, ISRAEL--(Marketwired - Oct 12, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced results of the food effect study of the Phase 3 formulation of its leading product candidate, Accordion Pill Carbidopa/Levodopa, or AP-CDLD. The results demonstrated that plasma concentrations of carbidopa and levodopa were similar, with no statistically significant differences in all PK parameters measured, when AP-CDLD was taken with various food compositions. This suggests that the treatment with AP-CDLD, intended to be taken b.i.d (two times a day) or t.i.d (three times a day) with food, is independent of the food content.
View More : http://www.marketwired.com/mw/release.do?id=2063079&sourceType=3
|
|
|